During the past decade, Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia" are "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Squamous Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia" in a lesser frequency.

Most popular intervention types in "Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Paclitaxel" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".